10:31 AM EDT, 03/28/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Thursday that it has started a phase 1 clinical study of NBI-1065890 for the potential treatment of certain neurological and neuropsychiatric conditions.

NBI-1065890 is an investigational oral, selective inhibitor of the vesicular monoamine transporter-2, or VMAT2, the company said, adding that these kinds of inhibitors have been clinically validated as effective treatments for hyperkinetic movement disorders.

The study will evaluate the compound's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults, the company said.

Price: 138.09, Change: +0.26, Percent Change: +0.19